Cost-effectiveness analysis of abiraterone, docetaxel or placebo plus androgen deprivation therapy for hormone-sensitive advanced prostate cancer.
Pedro Nazareth AguiarPui San TanSarah SimkoCarmelia Maria Noia BarretoBárbara de Souza GutierresAuro Del GiglioGilberto de Lima LopesPublished in: Einstein (Sao Paulo, Brazil) (2019)
The addition of chemotherapy to androgen deprivation therapy is more cost-effective than the addition of abiraterone to androgen deprivation therapy. However, discounts on abiraterone cost might improve cost-effectiveness.